Sophia specialises in placing global C-suite and board level executives in digital healthcare, pharmaceutical, biotechnology, medical device and diagnostics industries. She has a track record in venture capital and private equity. During her Ph.D., she opened her own consultancy advising funds on pre-deal due diligence and business development. Prior to True, Sophia was a key member of the global healthcare practice at Russell Reynolds Associates. She has a deep passion for transformational technology; she has placed CEOs/executive chairs for a number of VC and PE-backed companies that have since gone through successful exit. Her portfolio includes devising the board for a healthcare company pre-IPO, which then listed on the FTSE 100. Sophia is a published scientist, she holds a First Class Master’s degree from University College London in natural sciences, specializing in cell and molecular biology and science communication. She was nominated for the European Science Engineering and Technology Awards for her discovery of novel anti-cancer and anti-ageing therapeutic targets and won an MRC-funded scholarship in translational oncology at Imperial College London, using the latest cutting edge CRISPR/Cas9 genetic editing technology.